ArticleFrontiers in oncology2026
Global and regional burden of liver cancer attributable to drug use in elderly patients: a 1990-2021 analysis from the GBD study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global burden of liver cancer is undergoing an etiological shift, driven by population aging and the increasing complexity of pharmacological management. While Drug-Induced Liver Injury (DILI) is a recognized carcinogenic mechanism, the population-level impact remains under-quantified. This study aims to quantify the spatiotemporal trends of liver cancer burden attributable to drug use in the elderly population (aged 55+) and elucidate the drivers behind regional disparities. Methods: Leveraging data from the Global Burden of Disease (GBD) Study 2021, we analyzed incidence, mortality, and disability-adjusted life years (DALYs) across 204 countries and territories from 1990 to 2021. Adopting the Comparative Risk Assessment (CRA) framework, we estimated the specific burden by calculating the Population Attributable Fraction (PAF) relative to a theoretical minimum risk exposure level (TMREL) of zero drug use. Temporal trends were assessed using Estimated Annual Percentage Change (EAPC), and associations with the Socio-demographic Index (SDI) were evaluated to delineate developmental disparities. Results: Globally, the absolute number of deaths has steadily increased despite stable age-standardized rates. A distinct "SDI Divergence" was observed: High-SDI regions exhibited the most rapid escalation in burden (highest EAPC), driven by the "Opioid-Polypharmacy Nexus," whereas Low-SDI regions sustained a persistently high baseline burden due to unmet diagnostic needs. Demographic analysis revealed a stark male predominance and identified the 55-74 age group as the "active intervention window," accounting for the largest proportion of the global burden in terms of both mortality and DALYs. Discussion: The escalating burden of liver cancer attributable to drug use in the elderly underscores the "Cumulative Impact of Prolonged Exposure," where the intersection of physiological aging and complex drug use patterns amplifies hepatic risk. Mitigating this crisis requires stratified strategies: prioritizing "Capacity Building" (integrating screening into infectious disease programs) in resource-limited settings, and implementing strict "Stewardship" (pharmacovigilance and active deprescribing) in developed nations to curb this trajectory.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.